Enliven Therapeutics (ELVN) Research & Development (2019 - 2026)
Enliven Therapeutics' Research & Development was $29 million in Q2 2026, up 34.9% from $21.49 million a year earlier and up 40.2% from the prior quarter.
Powered by 
Analysis
Enliven Therapeutics (ELVN) Research & Development (2019 - 2026) Analysis & Trends
On a trailing twelve-month basis, Enliven Therapeutics' Research & Development was $89.15 million through Jun 30, 2026, up 0.9% year-over-year; for FY2025, it came in at $85.86 million, up 6.3% from FY2024.
- Research & Development has now increased for three consecutive years, with a five-year compound annual growth rate of 21.7% (FY2020 to FY2025).
- In earlier years, Research & Development was $80.78 million in FY2024 (+25.1%), $64.57 million in FY2023 (+108.2%), $31.02 million in FY2022 (-19.3%) and $38.44 million in FY2021 (+19.6%).
- The Q2 2026 figure marks the highest quarterly Research & Development in data going back to Q1 2019.
- Compared with a year earlier, Research & Development was higher in six of the last eight quarters, with growth averaging 8.7%.
- The best year-over-year quarter for Research & Development over five years was Q3 2023 (growth of 150.4%); the worst was Q3 2022 (a decline of 24.7%).
- Per Business Quant data, ELVN's Research & Development in the three quarters before Q2 2026 was $20.69 million (Q1 2026), $21.25 million (Q4 2025) and $18.23 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Enliven Therapeutics | 3.37 Bn | 3.37 Bn | - | 29.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.00 Mn |
| Mar 31, 2026 | 20.69 Mn |
| Dec 31, 2025 | 21.25 Mn |
| Sep 30, 2025 | 18.23 Mn |
| Jun 30, 2025 | 21.49 Mn |
| Mar 31, 2025 | 24.90 Mn |
| Dec 31, 2024 | 20.72 Mn |
| Sep 30, 2024 | 21.26 Mn |
| Jun 30, 2024 | 18.83 Mn |
| Mar 31, 2024 | 19.97 Mn |
| Dec 31, 2023 | 17.91 Mn |
| Sep 30, 2023 | 19.61 Mn |
| Jun 30, 2023 | 15.18 Mn |
| Mar 31, 2023 | 11.88 Mn |
| Dec 31, 2022 | 8.20 Mn |
| Sep 30, 2022 | 7.83 Mn |
| Jun 30, 2022 | 7.94 Mn |
| Mar 31, 2022 | 7.06 Mn |
| Dec 31, 2021 | 10.86 Mn |
| Sep 30, 2021 | 10.40 Mn |
API Access
Enliven Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ELVN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ELVN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ELVN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();